There is an increasingly strong possibility that TLD1433 will achieve double the one year CR rate of Keytruda, it's FDA approved competitor. It's even possible that a triple or more CR rate will be achieved. For those of us who have held this stock for years it seems like only a matter of time before FDA approval is granted. I wonder where the stock price might end up for a company with an FDA approved treatment for BCG-unresponsive NMIBC, that involves just two 90 minute sessions, has minimal side effects and in the majority of cases completely elimnates NMIBC, allowing patients to keep their bladders and live normal lives.
Right now the stock price is struggling to get to 30 cents while all of the information allowing me to make the above claims is publicly available online. If Theralase shareholders are correct there is an immense opportunity to make a lot of money available which very few investors are taking advantage of. Why is Theralase still flying under the radar? Here are my guesses.
1 - Our 90 day CR rate for the first 33 full dose patients is 42% Never mind the fact that our
potential 90 day CR rate is a mind-blowing
75.8% Our
actual current 90 day CR rate is
42%, about the same as Keytruda. We will have to wait another 3 months before our actual 33 patient CR rate is revealed to be 60 - 70% (and the 90 day CR rate should get higher and higher as more patients receive the optimized treatment)
2 - There has been no dedicated news release trumpeting the remarkable results achieved so far. The trial news has been buried inside a news release about Theralase's 3Q21 financial statements and in Theralase's newsletter located several levels deep on Theralase's website.
3 - Those involved in the trial are keeping mum. Just to give a few examples
-
The Carolina Urological Research Centre's Current Trials Page https://carolinaurologicresearchcenter.com/current-trials/ has no mention of the TLD1433 trial they are conducting.
The principal investigator Neal Shore recently authored this paper
Non-muscle-invasive bladder cancer: An overview of potential new treatment options which says only that the TLD1433 phase 2 trial is underway.
-T
he Virginia Urology Clinic Trials Page https://www.uro.com/about-us/clinical-trials-research/ has no reference to our trial
-The MidLantic Urology Clinical Research Page https://midlanticurology.com/clinical-research lists 8 bladder cancer trials being conducted there but does not mention our trial
This amazing opportunity to get very rich from a minimal investment may be around for a while yet!